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Abstract
Objectives: To audit the diagnostic yield and cost implica-
tions of the use of a ‘liver screen’ for inpatients with abnor-
mal liver function tests.
Design: We performed a retrospective audit of inpatients
with abnormal liver function tests. We analysed all investi-
gations ordered including biochemistry, immunology, vir-
ology and radiology. The final diagnosis was ascertained
in each case, and the diagnostic yield and cost per positive
diagnosis for each investigation were calculated.
Setting: St Thomas’ NHS Trust.
Participants: All inpatients investigated for abnormal liver
function tests over a 12-month period.
Main outcome measures:We calculated the percentage of
courses due to each diagnosis, the yield of each investiga-
tion and the cost per positive diagnosis for each
investigation.
Results: A total of 308 patients were included, and a final
diagnosis was made in 224 patients (73%) on the basis of
both clinical data and investigations. There was consider-
able heterogeneity in the tests included in an acute liver
screen. History and ultrasound yielded the most diagnoses
(40% and 30%, respectively). The yield of autoimmune and
metabolic screens was minimal.
Conclusions: Our results demonstrate the low yield of
unselected testing in patients with abnormal liver function
tests. A thorough history, ultrasound and testing for blood-
borne viruses are the cornerstones of diagnosis. Specialist
input should be sought before further testing. Prospective
studies to evaluate the yield and cost-effectiveness of dif-
ferent testing strategies are needed.
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Introduction
Liver disease is increasing and now accounts for 1.5%
of deaths in the United Kingdom.1 As a result, the
assessment of patients with both incidental and per-
sistently abnormal liver function tests (LFTs) is an
increasingly common clinical problem encountered
by the acute physician. The use of a ‘liver-screen’ to
test not only for viral causes of liver disease but also
for metabolic and inherited conditions is common
clinical practice,2–4 although there are limited data
to support such an approach in the inpatient settings.
Studies in the community suggest that the yield of
unselected testing is low. In studies of patients with
incidental derangement of their LFTs, the yield of a
‘liver screen’ was between 3 and 10%.5,6 In contrast, a
cause can be identiﬁed in over 75% of patients with
persistently elevated LFTs.7–9 This suggests that bio-
chemical liver screens can be safely delayed until a
persistent elevation of LFTs is demonstrated. The
only study of acutely jaundiced patients showed ima-
ging and clinical course to be the two most important
factors in making a diagnosis.10
While individual elements of a liver screen are rela-
tively low cost, unselected testing may result in sub-
stantial costs at a national level,11 both from direct
costs associated to testing and secondly in indirect
costs due to prolonged inpatient stay, without a sig-
niﬁcant improvement in diagnostic yield.
The aim of this audit was to evaluate the diagnos-
tic yield of investigations ordered as part of routine
clinical care for inpatients investigated for abnormal
LFTs at a large acute hospital.
Methods
Audit population
The hospital pathology records of every patient seen
between 1 January 2011 and 31 December 2011 were
reviewed. Requests for a-1-antitrypsin, caeruloplas-
min and liver auto-antibiodies were used to identify
patients undergoing an unselected liver screen.
Patients were excluded if they were being investigated
as an outpatient or aged under 18.
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Data collection
The electronic records system were used to obtain
demographic data, and the results of the following
tests for every patient: ultrasound liver, serology
for Hepatitis A, B, C, D, E, HIV, CMV and
EBV, liver auto-antibodies, caeruloplasmin, alpha-
1-anti-trypsin, ferritin, ANA, immunoglobulins,
LFTs and full blood count. Ultrasound reports
were reviewed, and patients were categorised as
having evidence of steatohepatitis, cirrhosis, biliary
dilatation, gallstones, gallbladder wall thickening,
ascites, portal hypertension and mass lesions. The
cost of investigations was provided by the hospital
laboratory department. This was used to calculate
the cost per positive diagnosis of each
investigation.
Diagnoses
Electronic records, clinic letters and discharge letters
were used to ascertain the clinical diagnosis for each
patient, and where a clinical diagnosis was not given
the clinical details and test results were reviewed by
one author (MM) who assigned the patients to a
diagnostic category.
Ethical approval
This was a retrospective case note review of routine
clinical data meeting the NHS deﬁnition of an audit12
and formal institutional review board approval was
therefore not required.
Results
A total of 308 had an inpatient request for at least one
of liver auto-antibodies, caeruloplasmim, a-1-
antitrypsin in 2011. The majority were male (n¼ 200,
65%) with a median age of 51.5 years (IQR 41–68).
Median peak ALT, ALP and Bilirubin was 76 IU/L
(IQR 33–294 IU/L, normal range 3–35 IU/L), 171 IU/
L (IQR 89–299 IU/L, normal range 30 to 120 IU/L)
and 23mmol/L (IQR 9–70mmol/L, normal range
3–17mmol/L), respectively. On review of clinical rec-
ords, no patient had a family history of Wilson’s dis-
ease or a-1-antitrypsin deﬁciency.
Testing
The frequency with which elements of the Liver
Screen were sent is shown in Table 1. No investigation
was organised in greater than 90% of patients. Testing
for all three common hepatitis viruses (A,B,C) was
carried out in 157 patients (51%). The combination
of an ultrasound and testing for viral hepatitis was
carried out in 110 patients (36%). Despite national
guidelines,13 an HIV test was only sent in 36% of
patients who had testing sent for either Hepatitis B
or C. Changes consistent with steatohepatitis was the
commonest ﬁnding on ultrasound (n¼ 78, 41% of
patients undergoing ultrasound, Table 2).
Diagnosis
No deﬁnitive diagnosis was made in 27% of
patients despite investigation. Alcohol-related liver
Table 1. Tests requested in investigation of abnormal liver function tests.
Test
Number (%)
test performed
Number (%)
diagnosis reacheda
Cost per
diagnosis
History N/A 90 (40) N/A
Ultrasound 189 (69) 67 (30) £158
Hepatitis A 168 (55) 6 (3) £857
Hepatitis B 238 (77) 9 (4) £1044
Hepatitis C 233 (76) 15 (7) £265
Autoimmune (all) 269 (87) 3 (1) £2796
Metabolic tests (any) 145 (47) 0 (0) b
aThis shows the percentage of diagnosis reached due predominantly to the test in cases where a diagnosis was reached; n¼ 224
bNo diagnoses were made via metabolic testing therefore a cost per diagnosis can not be calculated. a-1-antitrypsin, Caeruloplasmin
and Ferritin as screening tests costs £18.42 per patient.
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disease (22%), malignancies (11%), viral hepatitis
(10%) and gallstone disease (6%) were the com-
monest identiﬁed causes of abnormal LFTs
(Figure 1).
Yield and cost of diagnostic testing
Ultrasound and viral serology were the tests with the
highest diagnostic yield (Table 1). Measurement of
caeruloplasmin, a-1-antitrypsin or ferritin did not
contribute to the diagnosis in any cases. The cost to
yield ratio varied from £158 per positive test with
ultrasound to £2,976 per positive test with liver
auto-antibodies (Table 1).
Discussion
In this audit of investigations ordered as part of the
routine clinical investigations of over 300 inpatients
with abnormal LFTs, alcoholic liver disease was the
commonest diagnosis made. Despite extensive inves-
tigation, no diagnosis was made in over a quarter of
patients. History, ultrasound and testing for viral
causes were the most useful elements of the diagnostic
pathway. In this audit, there was no diagnostic value
in measuring caeruloplasmin, a-1-antitrypsin or fer-
ritin. The direct cost of these tests was substantial.
Although our audit does not directly address the
question of delayed discharges costs, it is plausible
Table 2. Findings on ultrasound.
Finding Frequency, %
Steatohepatitis 41
Splenomegaly 20
Ascites 20
Hepatomegaly 16
Gallbladder/biliary tract disease 16
Cirrhosis 13
Liver mass 5
Pancreatic abnormality 4
Note: 189 Patients underwent ultrasound.
Figure 1. Diagnosis for abnormal liver function tests. Alcoholic liver disease and biliary disease were the major causes of
abnormal liver function tests. The yield of autoimmune and metabolic testing was minimal.
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that additional testing may also contribute to indirect
costs by prolonging inpatient stay.
The second major ﬁnding is the heterogeneity of
the tests ordered. Only 36% of patients underwent
both an ultrasound and testing for hepatitis A, B
and C. Furthermore, despite national guidelines for
the routine testing of HIV, this was undertaken in
only one-third of patients. These ﬁndings highlight
the lack of consensus on the appropriate pathway
for investigating inpatients with abnormal LFTs.
We propose that a standardised approach be taken
to investigating these patients (Figure 2). Such an
approach would limit unnecessary testing and
ensure that patients undiagnosed after initial investi-
gation are referred to appropriate specialists for more
detailed investigations such as caeruloplasmin where
appropriate.
As this was a retrospective audit of clinical prac-
tice, the major limitation is that data are
retrospective and partially incomplete. Patients
were not systemically investigated, and we cannot
be certain that a ﬁnal diagnosis was not missed in a
number of patients. In particular, it is likely that
drug-induced liver function abnormalities accounted
for a higher proportion of cases. Because investiga-
tions were not ordered systematically, we did not
perform formal statistical comparisons of the diag-
nostic yield of each test, although the descriptive
statistics clearly highlight history, ultrasound and
blood-borne virus testing as the most useful diag-
nostic tools. As the aim of the audit was to assess
the yield of unselected testing, only patients
undergoing an unselected liver screen were included,
rather than all patients with bilirubineamia or
transaminitis, which may have introduced a selec-
tion bias. Some patients who underwent more tar-
geted testing, in particular for viral hepatitis, may
have been excluded. Such a bias would be likely to
Figure 2. Approach to investigating abnormal liver function tests in inpatients. A detailed history and review of medications are
key to establishing the underlying diagnosis. Initial diagnostic testing should be limited to imaging and blood-borne virus testing.
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strengthen our core results in showing that targeted
with history, ultrasound and virology yield the vast
majority of diagnoses, while further decreasing the
relative yield of biochemical and metabolic testing.
While diagnoses were assigned on the basis of com-
bined clinical and diagnostic data, ultrasound ﬁnd-
ings such as steatohepatitis can be non-speciﬁc. It is
possible that some cases classiﬁed as alcoholic hepa-
titis on the basis of an appropriate clinical history
and ultrasound ﬁndings may in fact have been due
to other undiagnosed causes. Finally, this audit
only included inpatients with abnormal LFTs. As
such the ﬁndings may not be generalisable to pri-
mary care or outpatient settings where a diﬀerent
diagnostic pathway may be appropriate.
Despite these limitations, this audit includes a
large number of both surgical and medical inpati-
ents with abnormal LFTs and is likely to reﬂect
everyday clinical practice. The ﬁndings of our
audit are in agreement with a previous study in
Denmark,10 which showed history and imaging to
be most useful when investigating hyperbilirubinae-
mia. The percentage of patients in whom no diag-
nosis was made is also similar to previous studies.
Clinical evaluation and directed testing diagnose
nearly all patients with an identiﬁable cause for
their abnormal LFTs. Our ﬁndings suggest that
the routine use of unselected testing in patients
with abnormal LFTs is both clinically unjustiﬁed
and is likely to result in signiﬁcant unnecessary
expenditure on both direct and indirect costs.
Approaches to decrease unselected testing such as
informing clinicians of the cost of tests14 should be
considered.
In conclusion, our audit demonstrates there is a
considerable heterogeneity in the evaluation of inpa-
tients with abnormal LFTs and that a number of
commonly requested tests have minimal yield in the
routine inpatient setting but result in substantial
expenditure. Our audit highlights the need for a pro-
spective evaluation of the yield and cost-eﬀectiveness
of diﬀerent testing strategies to enable the develop-
ment of a standardised approach to the investigation
of inpatients with abnormal LFTs. Such an approach
would be likely to improve both clinical and ﬁnancial
outcomes.
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